SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.

Highlights Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Equities

002603

CNE1000015S0

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 10/05/2024 am IST			5-day change	1st Jan Change
19.3 ^CNY	-1.48%		+2.50%	-16.34%

26/04	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
26/04	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04	CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26/04	CI
Yiling Pharmaceutical Gets Nod for China Clinical Trial of Tracheobronchitis Drug	06/12	MT
Yiling Pharmaceutical's Lianhua Qingke Tablets Gets Nod to Become Over-the-Counter Drug; Shares Up 4%	23/11	MT
Yiling Pharmaceutical Gets Nod to Trial Huoxia Cold Granules	17/11	MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Yiling Pharmaceutical Gets Green Light to Trial Acute Myeloid Leukemia Drug	24/23/24	MT
Yiling Pharmaceutical Gets Greenlight to Trial G201-Na Capsules	12/23/12	MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Announces Implementation of Cash Dividend for 2022, Payable on 17 July 2023	12/23/12	CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022	23/23/23	CI
Yiling Pharma's Hypertension Drug Passes Regulatory Evaluation in China	15/23/15	MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022	27/23/27	CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/23/25	CI
Yiling Pharma Unit Gets Marketing Rights of Rujietai Capsules	02/23/02	MT
Yiling Pharma Gets Regulatory Nod for Traditional Chinese Medicine	03/23/03	MT
Yiling Pharma’s Traditional Chinese Medicine Added to Government's Recommended Drugs For COVID-19	09/23/09	MT
Shijiazhuang Yiling Pharma Secures Regulatory Nod For Traditional Chinese Medicine Trial	23/22/23	MT
Yiling Pharma Denies Claims That COVID-19 Drug May Cause Liver Injury	20/22/20	MT
Shijiazhuang Yiling Pharmaceutical's Anti-Respiratory Disease Drug Enters Singaporean Market; Shares Down 4%	13/22/13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Equities

002603

CNE1000015S0

Highlights

Filters